343 related articles for article (PubMed ID: 27941285)
21. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
22. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
Li Z; Song W; Rubinstein M; Liu D
J Hematol Oncol; 2018 Dec; 11(1):142. PubMed ID: 30577797
[TBL] [Abstract][Full Text] [Related]
23. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
Khalil DN; Budhu S; Gasmi B; Zappasodi R; Hirschhorn-Cymerman D; Plitt T; De Henau O; Zamarin D; Holmgaard RB; Murphy JT; Wolchok JD; Merghoub T
Adv Cancer Res; 2015; 128():1-68. PubMed ID: 26216629
[TBL] [Abstract][Full Text] [Related]
24. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
[TBL] [Abstract][Full Text] [Related]
25. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.
Kalathil SG; Thanavala Y
Cancer Immunol Immunother; 2016 Jul; 65(7):813-9. PubMed ID: 26910314
[TBL] [Abstract][Full Text] [Related]
26. CAR T Cell Therapy Progress and Challenges for Solid Tumors.
Stern LA; Jonsson VD; Priceman SJ
Cancer Treat Res; 2020; 180():297-326. PubMed ID: 32215875
[TBL] [Abstract][Full Text] [Related]
27. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
29. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
[TBL] [Abstract][Full Text] [Related]
30. Emerging strategies in regulatory T-cell immunotherapies.
Gajewski TF; Chesney J; Curriel TJ
Clin Adv Hematol Oncol; 2009 Jan; 7(1):1-10; quiz 11-2. PubMed ID: 19288606
[TBL] [Abstract][Full Text] [Related]
31. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
Wang W; Xia X; Wu S; Guo M; Lie P; He J
Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
[TBL] [Abstract][Full Text] [Related]
33. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
35. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
37. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
[TBL] [Abstract][Full Text] [Related]
39. [Recent progress of cancer immunology and immunotherapy].
Kawakami Y
Nihon Rinsho; 2017 Feb; 75(2):175-180. PubMed ID: 30562849
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
Gjerstorff MF; Andersen MH; Ditzel HJ
Oncotarget; 2015 Jun; 6(18):15772-87. PubMed ID: 26158218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
